中国腹膜透析技术发展现状与未来  

Current status and future of peritoneal dialysis technology in China

作　　者：陈香美[1] 周建辉[1] 

机构地区：[1]解放军总医院肾病科全军肾脏病研究所肾脏疾病国家重点实验室,北京100853

出　　处：《中国实用内科杂志》2013年第6期413-415,共3页Chinese Journal of Practical Internal Medicine

摘　　要：腹膜透析是终末期肾脏疾病(ESRD)重要的治疗方法之一。目前全球10%～20%尿毒症患者采用腹膜透析进行治疗。持续非卧床腹膜透析(CAPD)是中国目前最主要的腹膜透析模式,约占80%。探索适宜中国人的腹膜透析剂量、推广国产具有自主知识产权的血液净化产品,做到规范医疗、扎实科研、促进转化、服务患者,不断探索和研究适合中国国情的腹膜透析治疗方法是中国医学科研工作者今后努力的方向。Peritoneal dialysis is one of the important therapeutic methods for end-stage renal disease （ESRD）. At present, it is used in 10% -20% patients with uremia. Continuous ambulatory peritoneal dialysis （CAPD）, as the main dialysis mode in China, accounts for 80%. The future direction of Chinese researchers may focus on：investigating the reasonable doses of dialysis in Chinese patients, promoting the blood purification products that have self-owned intellectual property, standardizing medical service, making research solid, pushing translational medicine forward, serving patients and continuing to explore the dialysis treatment methods for Chinese patients.

关 键 词：腹膜透析 终末期肾脏疾病 持续非卧床腹膜透析 

分 类 号：R459.5[医药卫生—治疗学]